EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PATIENT SATISFACTION AND QUALITY OF LIFE:

Murat Arik, Bronwyn Graves

Global Journal of Accounting and Finance · 12.06.2026 · 7 (1)

DOI: 10.47177/5btdy228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Journal of Accounting and Finance, online erschienen am 12.06.2026. Verfasst von Murat Arik und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study was to evaluate the effectiveness, potential savings, and patient satisfaction for the Urbanek Splint (US) in the treatment of temporomandibular joint disorders (TMDs) for the selected sample treated with the device, which was developed using patient-centered methods. A survey was sent to 844 potential participants who had been treated with the Urbanek Splint TMD treatment method, with a usable response rate of 30%. We use bootstrapped t-tests to test the severity of symptoms and quality of life (QOL) ratings before treatment and after treatment with the Urbanek Splint, and we also test differences between the previously treated (PT) and the not previously treated (NT) groups. We evaluated additional aggregated cost and usage information based on the FAIR Health, Inc. claims databases. This paper used Qualtrics survey software to collect survey responses, and exclusion criteria were the use of the US treatment method and over 18 years of age. The previously treated (PT) group reported an average 64% (p < 0.01) decrease in symptom severity after use with the US, and the not previously treated (NT) group reported an average 72% decrease (p < 0.01). The previously treated (PT) group reported an average 69% (p < 0.01) increase in QOL measures, and the not previously treated (NT) group reported an average 74% (p < 0.01) increase. Given the participant-reported previous cost of TMD treatment and the national cost of treating TMDs, initially using the US could potentially save $2,724 to $6,615 (discounted $2,215 to $5,379) for the average individual in our sample. The Urbanek Splint users in this study, both previously treated (PT) and not previously treated (NT) groups, show decreases in symptom severity, some complete elimination of symptoms, and increases in quality-of-life measures. Additionally, both previously treated (PT) and not previously treated (NT) groups show high satisfaction levels with the Urbanek Splint.

Zitieren

APA

Arik, M., & Graves, B. (2026). PATIENT SATISFACTION AND QUALITY OF LIFE:. Global Journal of Accounting and Finance, 7(1). https://doi.org/10.47177/5btdy228

Vancouver

Arik M, Graves B. PATIENT SATISFACTION AND QUALITY OF LIFE:. Global Journal of Accounting and Finance. 2026;7(1). doi:10.47177/5btdy228

BibTeX
@article{Arik2026,
  author = {Arik, Murat and Graves, Bronwyn},
  title = {PATIENT SATISFACTION AND QUALITY OF LIFE:},
  journal = {Global Journal of Accounting and Finance},
  year = {2026},
  volume = {7},
  number = {1},
  doi = {10.47177/5btdy228}
}
Kostenlos starten →